CYCLICA
23.3.2022 15:02:04 CET | Business Wire | Press release
Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. (“Arctoris”), a tech-enabled biopharma company that combines its unique automation with computational approaches to progress drug discovery, have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimer’s disease. This planned expansion of the partnership follows the results from an initial engagement that yielded positive results for targets related to both oncology and neurodegenerative disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005554/en/
“Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimers and other neurodegenerative diseases. The potential of combining our two specialties is very promising and we are extremely optimistic about the impact this partnership is expected to have on patients,” shares Naheed Kurji, Co-Founder, President and CEO of Cyclica.
Dr. Martin-Immanuel Bittner, MD DPhil FRSA , CEO of Arctoris, comments by sharing, “Our joint drug discovery program focuses on dual specificity inhibitors - a very promising yet also challenging modality. Cyclica is one of the leaders in this space, leveraging their structure-based and AI-directed molecule design for polypharmacology, while at Arctoris we have built a particular expertise in complex mechanistic enzymology and advanced cell-based models in neurodegeneration. This is a highly synergistic partnership, and I am excited about what we can achieve together for patients around the world in an indication area in dire need of new and better treatment options.”
Cyclica and Arctoris have long-term plans for their partnership as discussions are already underway about tackling additional therapeutic targets.
About Cyclica
Cyclica advances molecules that embrace the complexity of the disease. Our work spans dozens of collaborations with large pharma and biotech and several joint ventures. We are a passionate team of biotech and pharma professionals, biologists, chemists, and computer scientists who live and labour at the intersection of our collective expertise. To learn more about Cyclica and how we partner, please visit www.cyclicarx.com .
About Arctoris
Arctoris is a tech-enabled drug discovery company headquartered in Oxford and Boston. Arctoris combines its unique automation platform, Ulysses, with advanced computational approaches and a world-class team of seasoned drug hunters to guide and rapidly progress its wholly owned and partnered drug discovery programs in oncology and neurology. To learn more about Arctoris, please visit https://www.arctoris.com/ .
Forward Looking Information
This press release contains forward-looking statements and forward-looking information which include, among other things, plans to advance drug discovery programs by Cyclica and Arctoris. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors. Accordingly, you should not rely upon forward-looking statements as predictions of future events and we cannot assure you that the events reflected will be achieved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005554/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Expands Prebuilt AI Apps With New Production-Ready Applications to Accelerate Enterprise AI Adoption28.5.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] today released a new set of Prebuilt AI Apps: ready-to-use agentic applications designed to drive efficiency and business growth by accelerating the integration of AI into enterprise processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528283268/en/ Prebuilt AI Apps are ready-to-use agentic applications designed to accelerate the integration of AI into enterprise processes, driving efficiency and supporting business growth. In developing the Prebuilt AI Apps, Reply has identified key areas within enterprise processes where AI can create tangible operational value and turned them intoreusable assets, combining deep process knowledge, curated datasets, domain ontologies and reusable agentic flows in robust, secure and production-ready solutions. Each application can be further customised and extended through integration with enterprise systems, internal data and knowledge bases, while maintaining
Klarna Partners With Arrive for Parking in 15 Markets28.5.2026 09:56:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has partnered with Arrive, a leading global mobility platform, to bring seamless and flexible payment options to millions of consumers across 15 markets. Through the partnership, drivers will be able to pay for parking using Klarna’s Pay in Full, which will be available directly in Arrive’s EasyPark app, ensuring payments can be made instantly. This provides consumers with more flexibility and control over their everyday spending, and builds on Klarna's growing presence in everyday spending and saving, where consumers increasingly use Klarna for recurring, low-friction purchases alongside savings products like Klarna Balance. Arrive, formerly EasyPark Group, operates one of the world’s largest digital parking networks, facilitating high frequency payments across millions of spots in more than 20,000 cities and 90 countries. By providing the digital infrastructure that helps individuals and decision-makers make smarter urba
Navan Unlocks Savings for Travelers with First SAS NDC Direct Connect28.5.2026 09:01:00 CEST | Press release
Direct connection gives travelers access to lower fares and streamlined post-booking services Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced a New Distribution Capability (NDC) integration with Scandinavian Airlines (SAS). By allowing the airline to share its fares, availability, and offers directly in real time, the integration provides an expanded portfolio of SAS fares and services to Navan customers. This makes Navan the first Travel Management Company (TMC) to access SAS NDC content via a direct connection, leveraging version 21.3 of the NDC API. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528812727/en/ Direct connection gives travelers access to lower fares and streamlined post-booking services “Our Modern Airline Retailing journey is centered on delivering more relevant offers, greater transparency, and better value for travelers,” said Edward Fotheringham, VP S
KKR to Open New Office in Milan, Strengthening Long-Term Commitment to Italy28.5.2026 09:00:00 CEST | Press release
New office reflects KKR’s localisation strategy and opportunity in Italy’s evolving investment landscape KKR, a leading global investment firm, today announced plans to open an office in Milan, further strengthening its long-term commitment to Italy and expanding its local presence in one of Europe’s largest economies. The office will support the firm’s investment activity across Private Equity, Real Assets, Credit and Insurance, while deepening client partnerships and advancing the continued development of KKR’s private wealth business in Italy. Italy has been an important market for KKR for over two decades, with over €10 billion of capital deployed since 2005 across Private Equity, Real Assets and Credit. The firm’s investments include FiberCop, Europe’s first wholesale-only, open-access fibre network, Enilive, a key player in advancing Italy’s energy transition, and CMC, a sustainable packaging leader using robotics to drive innovation. These investments reflect KKR’s focus on part
Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease28.5.2026 09:00:00 CEST | Press release
A new qualitative literature review provides a comprehensive model of the patient experience of OFF episodes, identifying 132 distinct motor, non-motor and quality-of-life impacts1 The research highlights OFF episode as a complex, multifaceted experience, highlighting the profound and often invisible struggles faced by people with Parkinson’s disease1 Additional analyses of levodopa inhalation powder (INBRIJA®) confirm its clinical profile as a rapid, reliable and well-tolerated on-demand treatment for OFF episodes2,3 Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new research at the World Parkinson Congress (WPC) 2026 that uncovers the multifaceted burden of "OFF" episodes in Parkinson's disease (PD). The qualitative literature review demonstrates that these episodes are not only a re-emergence of motor symptoms, but also a complex mix of debilitating motor and non-motor symptoms that impact the lives of people with Parki
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom